The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study
Over the last years has emerged the urgent need for the identification of reliable prognostic biomarkers able to potentially identify metastatic castration-resistant prostate cancer (mCRPC) patients most likely to benefit from Radium-223 (Ra-223) since baseline. In the present monocentric retrospect...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/11/3213 |
id |
doaj-0f61880411c44294aeb2de3325429e9f |
---|---|
record_format |
Article |
spelling |
doaj-0f61880411c44294aeb2de3325429e9f2020-11-25T04:00:50ZengMDPI AGCancers2072-66942020-10-01123213321310.3390/cancers12113213The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept StudyMatteo Bauckneht0Sara Elena Rebuzzi1Alessio Signori2Maria Isabella Donegani3Veronica Murianni4Alberto Miceli5Roberto Borea6Stefano Raffa7Alessandra Damassi8Marta Ponzano9Fabio Catalano10Valentino Martelli11Cecilia Marini12Francesco Boccardo13Silvia Morbelli14Gianmario Sambuceti15Giuseppe Fornarini16Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyDepartment of Health Sciences (DISSAL), University of Genova, Largo R. Benzi 10, 16132 Genova, ItalyDepartment of Health Sciences (DISSAL), University of Genova, Largo R. Benzi 10, 16132 Genova, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyDepartment of Health Sciences (DISSAL), University of Genova, Largo R. Benzi 10, 16132 Genova, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyDepartment of Health Sciences (DISSAL), University of Genova, Largo R. Benzi 10, 16132 Genova, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyDepartment of Health Sciences (DISSAL), University of Genova, Largo R. Benzi 10, 16132 Genova, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyNuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyAcademic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyNuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyNuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, ItalyOver the last years has emerged the urgent need for the identification of reliable prognostic biomarkers able to potentially identify metastatic castration-resistant prostate cancer (mCRPC) patients most likely to benefit from Radium-223 (Ra-223) since baseline. In the present monocentric retrospective study, we analyzed the prognostic power of systemic inflammation biomarkers and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET)-derived parameters and their potential interplay in this clinical setting. The following baseline laboratory parameters were collected in 59 mCRPC patients treated with Ra-223: neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), platelets-to-lymphocyte ratio (PLR), and systemic inflammation index (SII), while maximum Standardized Uptake Value, Metabolic Tumor Volume (MTV), and Total Lesion Glycolysis (TLG) were calculated in the 48 of them submitted to baseline FDG-PET. At the univariate analysis, NLR, dNLR, MTV, and TLG were able to predict the overall survival (OS). However, only NLR and MTV were independent predictors of OS at the multivariate analysis. Additionally, the occurrence of both increased NLR and MTV at baseline identified mCRPC patients at higher risk for lower long-term survival after treatment with Ra-223. In conclusion, the degree of systemic inflammation, the quantification of the metabolically active tumor burden and their combination might represent potentially valuable tools for identifying mCRPC patients who are most likely to benefit from Ra-223. However, further studies are needed to reproduce these findings in larger settings.https://www.mdpi.com/2072-6694/12/11/3213metastatic castration resistant prostate cancerradium-223neutrophil-to-lymphocyte ratiolymphocyte-to-monocyte ratioplatelet-to-lymphocyte ratiosystemic inflammation index |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matteo Bauckneht Sara Elena Rebuzzi Alessio Signori Maria Isabella Donegani Veronica Murianni Alberto Miceli Roberto Borea Stefano Raffa Alessandra Damassi Marta Ponzano Fabio Catalano Valentino Martelli Cecilia Marini Francesco Boccardo Silvia Morbelli Gianmario Sambuceti Giuseppe Fornarini |
spellingShingle |
Matteo Bauckneht Sara Elena Rebuzzi Alessio Signori Maria Isabella Donegani Veronica Murianni Alberto Miceli Roberto Borea Stefano Raffa Alessandra Damassi Marta Ponzano Fabio Catalano Valentino Martelli Cecilia Marini Francesco Boccardo Silvia Morbelli Gianmario Sambuceti Giuseppe Fornarini The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study Cancers metastatic castration resistant prostate cancer radium-223 neutrophil-to-lymphocyte ratio lymphocyte-to-monocyte ratio platelet-to-lymphocyte ratio systemic inflammation index |
author_facet |
Matteo Bauckneht Sara Elena Rebuzzi Alessio Signori Maria Isabella Donegani Veronica Murianni Alberto Miceli Roberto Borea Stefano Raffa Alessandra Damassi Marta Ponzano Fabio Catalano Valentino Martelli Cecilia Marini Francesco Boccardo Silvia Morbelli Gianmario Sambuceti Giuseppe Fornarini |
author_sort |
Matteo Bauckneht |
title |
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study |
title_short |
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study |
title_full |
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study |
title_fullStr |
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study |
title_full_unstemmed |
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study |
title_sort |
prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with radium-223: a proof of concept study |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-10-01 |
description |
Over the last years has emerged the urgent need for the identification of reliable prognostic biomarkers able to potentially identify metastatic castration-resistant prostate cancer (mCRPC) patients most likely to benefit from Radium-223 (Ra-223) since baseline. In the present monocentric retrospective study, we analyzed the prognostic power of systemic inflammation biomarkers and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET)-derived parameters and their potential interplay in this clinical setting. The following baseline laboratory parameters were collected in 59 mCRPC patients treated with Ra-223: neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), platelets-to-lymphocyte ratio (PLR), and systemic inflammation index (SII), while maximum Standardized Uptake Value, Metabolic Tumor Volume (MTV), and Total Lesion Glycolysis (TLG) were calculated in the 48 of them submitted to baseline FDG-PET. At the univariate analysis, NLR, dNLR, MTV, and TLG were able to predict the overall survival (OS). However, only NLR and MTV were independent predictors of OS at the multivariate analysis. Additionally, the occurrence of both increased NLR and MTV at baseline identified mCRPC patients at higher risk for lower long-term survival after treatment with Ra-223. In conclusion, the degree of systemic inflammation, the quantification of the metabolically active tumor burden and their combination might represent potentially valuable tools for identifying mCRPC patients who are most likely to benefit from Ra-223. However, further studies are needed to reproduce these findings in larger settings. |
topic |
metastatic castration resistant prostate cancer radium-223 neutrophil-to-lymphocyte ratio lymphocyte-to-monocyte ratio platelet-to-lymphocyte ratio systemic inflammation index |
url |
https://www.mdpi.com/2072-6694/12/11/3213 |
work_keys_str_mv |
AT matteobauckneht theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT saraelenarebuzzi theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT alessiosignori theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT mariaisabelladonegani theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT veronicamurianni theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT albertomiceli theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT robertoborea theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT stefanoraffa theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT alessandradamassi theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT martaponzano theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT fabiocatalano theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT valentinomartelli theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT ceciliamarini theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT francescoboccardo theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT silviamorbelli theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT gianmariosambuceti theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT giuseppefornarini theprognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT matteobauckneht prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT saraelenarebuzzi prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT alessiosignori prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT mariaisabelladonegani prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT veronicamurianni prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT albertomiceli prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT robertoborea prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT stefanoraffa prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT alessandradamassi prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT martaponzano prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT fabiocatalano prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT valentinomartelli prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT ceciliamarini prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT francescoboccardo prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT silviamorbelli prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT gianmariosambuceti prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy AT giuseppefornarini prognosticroleofbaselinemetabolictumorburdenandsystemicinflammationbiomarkersinmetastaticcastrationresistantprostatecancerpatientstreatedwithradium223aproofofconceptstudy |
_version_ |
1724448896230359040 |